Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.270
-0.150 (-6.20%)
At close: Sep 12, 2025, 4:00 PM EDT
2.320
+0.050 (2.18%)
After-hours: Sep 12, 2025, 7:59 PM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $59.95M in the quarter ending June 30, 2025, with 92.73% growth. This brings the company's revenue in the last twelve months to $241.53M, up 636.99% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm)
$241.53M
Revenue Growth
+636.99%
P/S Ratio
2.97
Revenue / Employee
$288,216
Employees
838
Market Cap
821.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
Dec 31, 2023 | 1.19M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IOVA News
- 15 days ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 22 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 - Seeking Alpha
- 26 days ago - Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma - GlobeNewsWire
- 5 weeks ago - Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 - GlobeNewsWire
- 7 weeks ago - Here's why Iova stock surged 32% today and why the rally might not be over - Invezz
- 2 months ago - Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha